Oral meds at their currently available doses have typically ranged from 5%-7%, though newer studies with higher doses of oral semaglutide are showing results in the 10%-12% range over 68 weeks. So while injections still lead, oral GLP-1 medications are evolving quickly
However, with the steep price, it is hard to justify
The FDA prescribing information does not contraindicate tirzepatide in patients who have undergone gallbladder removal, and the medication's effectiveness is not affected by gallbladder status
Working with the students is especially rewarding
The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]